Sage Impresses With Second Postpartum Depression Therapy
Positive top-line Phase III data with Sage's second lead positive allosteric modulator at GABA receptors, SAGE-217, in postpartum depression continues to back the US biotech's approach to the devastating condition.
You may also be interested in...
Sage will initiate three new trials to support FDA approval of the drug for post-partum depression and major depressive disorder, with data anticipated in 2021.
The company said it will update investors on the path forward for zuranolone in major depressive disorder after finalizing discussions with the US FDA. It would not confirm if a meeting had taken place yet.
Sage Therapeutics points to patient compliance and selection as factors in its failed trial of SAGE-217. The company sees positive implications in the data as it waits for other SAGE-217 studies.